Artem Shvartsbart

Most-cited papers

1. Discovery of Potent and Selective Inhibitors of Wild-Type and Gatekeeper Mutant Fibroblast Growth Factor Receptor (FGFR) 2/3.

   Artem Shvartsbart, Jeremy J. Roach, Michael R. Witten, H. Koblish +22 more

   2022Journal of Medicinal Chemistry20 citations Open access

   Semantic Scholar

   Save

2. Discovery of INCB159020, an Orally Bioavailable KRAS G12D Inhibitor.

   Qin-Da Ye, Artem Shvartsbart, Zhenwu Li, Pei Gan +30 more

   2025Journal of Medicinal Chemistry15 citations Open access

   Semantic Scholar

   Save

3. Abstract 4503: Preclinical characterization of PRT7732: A highly potent, selective, and orally bioavailable targeted protein degrader of SMARCA2

   Artem Shvartsbart, Koichi Ito, J. Rager, Michael Hulse +33 more

   2024Cancer Research3 citations

   Semantic Scholar

   Save

4. Abstract B113: Discovery of PRT3789, a first-in-class potent and selective SMARCA2 degrader in clinical trials for the treatment of patients with SMARCA4 mutated cancers

   Koichi Ito, Michael Hulse, Anjana Agarwal, Jack Carter +43 more

   2023Molecular Cancer Therapeutics3 citations

   Semantic Scholar

   Save

5. Abstract 6277: Selective and orally bioavailable SMARCA2 targeted degraders induce synthetic lethality in SMARCA4- deficient solid tumor

   Koichi Ito, Artem Shvartsbart, J. Rager, A. Agarwal +28 more

   2023Cancer Research0 citations

   Semantic Scholar

   Save

6. Discovery of potent and selective PI3Kγ inhibitors via elaboration of a designed fragment and identification of key metabolites

   Andrew W. Buesking, Stacey Shepard, Li-Hua Shao, Nikoo Falahatpisheh +19 more

   20200 citations Open access

   Semantic Scholar

   Save

7. Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma

   Artem Shvartsbart, Stacey Shepard, Andrew P. Combs, Li-Xin Shao +6 more

   20160 citations

   Semantic Scholar

   Save